ICPT Fundamental Analysis - INTERCEPT PHARMACEUTICALS IN

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to ICPT. ICPT was compared to 549 industry peers in the Biotechnology industry. ICPT may be in some trouble as it scores bad on both profitability and health. ICPT does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

ICPT had negative earnings in the past year.

In the past year ICPT has reported a negative cash flow from operations.

In the past 5 years ICPT reported 4 times negative net income.

In the past 5 years ICPT always reported negative operating cash flow.

1.2 Ratios

ICPT has a Return On Assets of -15.67%. This is amongst the best in the industry. ICPT outperforms 84.91% of its industry peers.

ICPT's Return On Equity of -85.76% is in line compared to the rest of the industry. ICPT outperforms 45.94% of its industry peers.

		Industry Rank	Sector Rank
ROA	-15.67%
ROE	-85.76%
ROIC	N/A

ROA(3y)-8.21%

ROA(5y)-26.21%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ICPT has a Gross Margin of 99.80%. This is amongst the best in the industry. ICPT outperforms 99.17% of its industry peers.

ICPT's Gross Margin has been stable in the last couple of years.

ICPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	99.8%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.45%

GM growth 5Y0.15%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ICPT does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ICPT has been increased compared to 1 year ago.

ICPT has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -5.03, we must say that ICPT is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -5.03, ICPT is doing worse than 66.17% of the companies in the same industry.

ICPT has a Debt/Equity ratio of 3.12. This is a high value indicating a heavy dependency on external financing.

With a Debt to Equity ratio value of 3.12, ICPT is not doing good in the industry: 85.41% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	3.12
Debt/FCF	N/A
Altman-Z	-5.03

ROIC/WACCN/A

WACC10.19%

2.3 Liquidity

A Current Ratio of 4.22 indicates that ICPT has no problem at all paying its short term obligations.

With a Current ratio value of 4.22, ICPT perfoms like the industry average, outperforming 42.45% of the companies in the same industry.

A Quick Ratio of 4.22 indicates that ICPT has no problem at all paying its short term obligations.

ICPT has a Quick ratio of 4.22. This is comparable to the rest of the industry: ICPT outperforms 43.62% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.22
Quick Ratio	4.22

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ICPT have decreased strongly by -125.05% in the last year.

ICPT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.64%.

Measured over the past years, ICPT shows a quite strong growth in Revenue. The Revenue has been growing by 16.88% on average per year.

EPS 1Y (TTM)-125.05%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-98.97%

Revenue 1Y (TTM)14.64%

Revenue growth 3Y4.27%

Revenue growth 5Y16.88%

Sales Q2Q%14.44%

3.2 Future

The Earnings Per Share is expected to decrease by -22.89% on average over the next years. This is quite bad

Based on estimates for the next years, ICPT will show a small growth in Revenue. The Revenue will grow by 1.71% on average per year.

EPS Next Y-122.07%

EPS Next 2Y-41.22%

EPS Next 3Y-33.62%

EPS Next 5Y-22.89%

Revenue Next Year3.67%

Revenue Next 2Y6.35%

Revenue Next 3Y4.21%

Revenue Next 5Y1.71%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ICPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

With a Price/Forward Earnings ratio of 9.11, the valuation of ICPT can be described as very reasonable.

99.00% of the companies in the same industry are more expensive than ICPT, based on the Price/Forward Earnings ratio.

When comparing the Price/Forward Earnings ratio of ICPT to the average of the S&P500 Index (35.24), we can say ICPT is valued rather cheaply.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	9.11

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as ICPT's earnings are expected to decrease with -33.62% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-41.22%

EPS Next 3Y-33.62%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ICPT does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

INTERCEPT PHARMACEUTICALS IN

NASDAQ:ICPT (11/7/2023, 8:02:20 PM)

After market: 19 0 (0%)

+0.04 (+0.21%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-06 2023-11-06/amc

Earnings (Next)02-29 2024-02-29/amc

Inst Owners0.17%

Inst Owner Change0%

Ins Owners10.38%

Ins Owner Change0%

Market Cap794.39M

Analysts70

Price Target19.38 (2%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)95.4%

Min EPS beat(2)73.02%

Max EPS beat(2)117.78%

EPS beat(4)2

Avg EPS beat(4)-7.36%

Min EPS beat(4)-203.66%

Max EPS beat(4)117.78%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)0.75%

Min Revenue beat(2)-1.65%

Max Revenue beat(2)3.15%

Revenue beat(4)1

Avg Revenue beat(4)-2.32%

Min Revenue beat(4)-7.75%

Max Revenue beat(4)3.15%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)6.63%

PT rev (3m)24.59%

EPS NQ rev (1m)0%

EPS NQ rev (3m)660.22%

EPS NY rev (1m)0%

EPS NY rev (3m)3.74%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0.01%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0.24%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	9.11
P/S	2.5
P/FCF	N/A
P/OCF	N/A
P/B	11.06
P/tB	11.06
EV/EBITDA	N/A

EPS(TTM)-1.33

EYN/A

EPS(NY)2.09

Fwd EY10.98%

FCF(TTM)-1.5

FCFYN/A

OCF(TTM)-1.51

OCFYN/A

SpS7.6

BVpS1.72

TBVpS1.72

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-15.67%
ROE	-85.76%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	99.8%
FCFM	N/A

ROA(3y)-8.21%

ROA(5y)-26.21%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.45%

GM growth 5Y0.15%

F-Score3

Asset Turnover0.81

Health

		Industry Rank	Sector Rank
Debt/Equity	3.12
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	49.34%
Cap/Sales	0.06%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.22
Quick Ratio	4.22
Altman-Z	-5.03

F-Score3

WACC10.19%

ROIC/WACCN/A

Cap/Depr(3y)78.24%

Cap/Depr(5y)53.92%

Cap/Sales(3y)0.53%

Cap/Sales(5y)0.43%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-125.05%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-98.97%

EPS Next Y-122.07%

EPS Next 2Y-41.22%

EPS Next 3Y-33.62%

EPS Next 5Y-22.89%

Revenue 1Y (TTM)14.64%

Revenue growth 3Y4.27%

Revenue growth 5Y16.88%

Sales Q2Q%14.44%

Revenue Next Year3.67%

Revenue Next 2Y6.35%

Revenue Next 3Y4.21%

Revenue Next 5Y1.71%

EBIT growth 1Y30.28%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-9.22%

EBIT Next 3Y46.24%

EBIT Next 5YN/A

FCF growth 1Y2.61%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-1.28%

OCF growth 3YN/A

OCF growth 5YN/A

INTERCEPT PHARMACEUTICALS IN (ICPT) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens